Sisram Medical Toekomstige groei

SEHK:1696 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	476	46	N/A	42	2
12/31/2025	433	40	N/A	26	3
12/31/2024	384	33	N/A	23	3
6/30/2024	356	24	33	40	N/A
3/31/2024	358	28	34	42	N/A
12/31/2023	359	31	35	44	N/A
9/30/2023	355	35	-5	32	N/A
6/30/2023	352	38	-46	19	N/A
3/31/2023	353	39	-44	21	N/A
12/31/2022	354	40	-42	22	N/A
9/30/2022	349	38	-11	22	N/A
6/30/2022	344	35	19	22	N/A
3/31/2022	319	33	24	27	N/A
12/31/2021	294	31	29	32	N/A
9/30/2021	255	28	35	40	N/A
6/30/2021	216	24	42	47	N/A
3/31/2021	189	19	29	36	N/A
12/31/2020	162	13	16	26	N/A
9/30/2020	161	13	10	19	N/A
6/30/2020	160	13	4	12	N/A
3/31/2020	167	17	11	17	N/A
12/31/2019	174	21	18	21	N/A
9/30/2019	167	22	19	21	N/A
6/30/2019	161	24	19	22	N/A
3/31/2019	158	23	17	19	N/A
12/31/2018	154	22	15	16	N/A
9/30/2018	151	18	13	14	N/A
6/30/2018	149	14	10	11	N/A
3/31/2018	143	12	N/A	14	N/A
12/31/2017	137	11	N/A	17	N/A
9/30/2017	131	11	N/A	18	N/A
6/30/2017	126	10	N/A	19	N/A
3/31/2017	123	11	N/A	20	N/A
12/31/2016	118	8	N/A	16	N/A
12/31/2015	110	8	N/A	16	N/A
12/31/2014	101	6	N/A	23	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 1696 ( 24.2% per jaar) ligt boven de spaarquote ( 2.3% ).

Winst versus markt: De winst van 1696 ( 24.2% per jaar) zal naar verwachting sneller groeien dan de Hong Kong markt ( 11.5% per jaar).

Hoge groeiwinsten: De winst van 1696 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 1696 ( 11.6% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.8% per jaar).

Hoge groei-inkomsten: De omzet van 1696 ( 11.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 1696 zal naar verwachting over 3 jaar laag zijn ( 8.2 %).

Sisram Medical Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

Sisram Medical Ltd Provides Earnings Guidance for the Year Ending December 31, 2021

Sisram Medical Ltd Provides Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

Sisram Medical Ltd Announces Appointment of Jiahong LI New Chief Financial Officer, Effective 29 October 2024

What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 24%

Sisram Medical Ltd Receives Product Approval from the National Medical Products Administration

First half 2024 earnings released: EPS: US$0.023 (vs US$0.04 in 1H 2023)

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Dividend of HK$0.16 announced

Sisram Medical Ltd to Report First Half, 2024 Results on Aug 21, 2024

Sisram Medical Ltd Declares A Final Dividend, Payable on or Around 9 September 2024

Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Sisram Medical Ltd, Annual General Meeting, Jun 24, 2024

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Sisram Medical Ltd Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2023

Sisram Medical Ltd to Report Fiscal Year 2023 Results on Mar 20, 2024

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Investor sentiment deteriorates as stock falls 20%

Now 21% overvalued

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Sisram Medical Ltd Announces the Registration Application of Profhilo

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 19%

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

First half 2023 earnings released: EPS: US$0.04 (vs US$0.044 in 1H 2022)

Upcoming dividend of HK$0.17 per share at 2.3% yield

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Sisram Medical Ltd Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable 07 September 2023

Sisram Medical Announces the Launch of Alma Veil for the U.S. Market

Sisram Medical Ltd. Receives the Clearance from the U.S. Food and Drug Administration

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 16%

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

Sisram Medical Ltd, Annual General Meeting, Jun 28, 2023

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.086 (vs US$0.069 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Sisram Medical Ltd Announces Resignation of Mr. Guojun Bu from the Position of Executive Director of the Company with Effect from January 1, 2023

Investor sentiment improved over the past week

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Less than half of directors are independent

Investor sentiment improved over the past week

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Investor sentiment deteriorated over the past week

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

First half 2022 earnings released: EPS: US$0.044 (vs US$0.037 in 1H 2021)

Sisram Medical Ltd SHARE to Be Deleted from OTC Equity

Upcoming dividend of HK$0.16 per share

Sisram Medical Ltd to Report Q2, 2022 Results on Aug 19, 2022

Sisram Medical Ltd Declares Final Dividend for the Year Ended December 31, 2021, Payable on or Around 2 September 2022

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Investor sentiment deteriorated over the past week

Sisram Medical Ltd Announces Phase IIb Clinical Result on Submental Fat Reduction of JS-001

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sisram Medical Ltd Announces Resignation of Yao WANG as Non-Executive Director

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely